Relevant bibliographies by topics / European Pharmacopoeia

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'European Pharmacopoeia'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'European Pharmacopoeia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "European Pharmacopoeia"

1

Moiseev, S. V., N. E. Kuz’mina, and A. I. Luttseva. "NMR as Used in the Russian and Foreign Pharmacopoeias for Quality Control of Medicinal Products." Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 12, no. 1 (February 18, 2022): 8–23. http://dx.doi.org/10.30895/1991-2919-2022-12-1-8-23.

Full text
Abstract:
The ongoing development of the Pharmacopoeia of the Eurasian Economic Union and the current trend for harmonisation of the Russian Pharmacopoeia with the world leading pharmacopoeias suggest the necessity of studying how different pharmacopoeias use nuclear magnetic resonance (NMR) for quality control of medicinal products. The aim of the study was to compare the extent of medicine quality characteristics assessed by NMR in the Russian and foreign pharmacopoeias. The review summarises the experience of various national and world pharmacopoeias in using the NMR method for quality control of medicines and certification of pharmacopoeial reference materials. The comparative analysis covered the following quality parameters: active ingredient identification, determination of the composition of non-stoichiometric compounds, determination of the average polymer chain length in polymers and block copolymers, determination of the absolute content of the active ingredient, identification and quantification of impurities, polymorphism, and crystallinity. It was shown that the United States and Japanese Pharmacopoeias are leading the way in introducing the NMR method into pharmacopoeial analysis. There have been some positive trends in the introduction of the NMR method in the State Pharmacopoeia of the Russian Federation as well. It was concluded that changes are needed in the general chapters “Nuclear Magnetic Resonance Spectroscopy” and “Reference Standards” of the State Pharmacopoeia of the Russian Federation, 14th ed. in order to harmonise the texts with those of the Eurasian Pharmacopoeia and the European Pharmacopoeia and to allow for the possibility of direct identification of a substance by complex analysis of NMR spectral data, without comparing the test sample and the reference standard spectra. The NMR method should be included in the list of absolute methods used for determination of purity of primary chemical reference substances during certification.
APA, Harvard, Vancouver, ISO, and other styles
2

Grizodoub, Oleksandr. "Twenty Years of The State Pharmacopoeia of Ukraine: The Experience of Establishing the First National Pharmacopoeia in The Post-Soviet Area." SSP Modern Pharmacy and Medicine 1, no. 2 (October 14, 2021): 1–20. http://dx.doi.org/10.53933/sspmpm.v1i2.22.

Full text
Abstract:
The quality and life expectancy of the population depends on the level of access to modern, high-quality, effective and evidence-based medical and pharmaceutical care. These types of care play a significant role in the pharmacotherapy of cardiovascular disease (CVD), which is one of the main medical, biological and socio-economic problems of society. CVDs cause 67% of all deaths in Ukraine. For comparison: in France and Japan, this component in the structure of mortality is 29%, in the United States - 31%. Heart attacks are one of the main nosologies that cause high mortality from COVID. The 1st October, 2021 marks 20 years since the introduction of the State Pharmacopoeia of Ukraine. The purpose of the study was to experience of creating the first national pharmacopoeia in the post-Soviet space. Ukraine, the first in the post-Soviet space, managed to create its own State Pharmacopoeia, which is fully harmonized with the European Pharmacopoeia and takes into account national specifics. The State Pharmacopoeia of Ukraine relies on its own National system of pharmacopoeial standard samples and pharmacopoeial program of professional testing of control laboratories as feedback from users. The State Pharmacopoeia of Ukraine is not funded by the state, and the Pharmacopoeia Center is a completely self-supporting structure. In general, the State Pharmacopoeia of Ukraine can be considered the best National Pharmacopoeia in the post-Soviet space.
APA, Harvard, Vancouver, ISO, and other styles
3

Vodyakova, M. A., A. R. Sayfutdinova, E. V. Melnikova, and Yu V. Olefir. "Comparison of the World Pharmacopoeias’ Requirements for the Quality of Cell Lines." BIOpreparations. Prevention, Diagnosis, Treatment 20, no. 3 (September 18, 2020): 159–73. http://dx.doi.org/10.30895/2221-996x-2020-20-3-159-173.

Full text
Abstract:
The cell line is one of the necessary components of a biomedical cell product (BMCP) which can include only viable human cells. In addition, human, animal, insect, or bacterial cell lines can be used as a substrate for the production of some biological drugs. The list of quality parameters and test methods for medicinal products quality control are specified in the State Pharmacopoeia of the Russian Federation, but it contains only a few general monographs on blood products and a few requirements for cell lines as substrates for the production of biological drugs (which cover all types of cells). Currently, there is no regulatory document comparable to the State Pharmacopoeia of the Russian Federation that would contain requirements and test methods for BMCP quality control in the Russian Federation. Thus, one of the issues that arises both during quality control and approval of BMCPs is the lack of a regulatory document defining requirements for BMCP quality parameters and test methods. However, some general monographs of the Russian Pharmacopoeia and other pharmacopoeias can be used for quality control of both cell lines and non-cellular components. The aim of the study was to analyse and compare different pharmacopoeial requirements for the quality of cell lines used as components in human cell- and tissue-based products (comparable to BMCPs), which could be used in BMCP quality control. The paper analyses general monographs of the United States Pharmacopoeia (USP), European Pharmacopoeia (Ph. Eur.), Japanese Pharmacopoeia, Pharmacopoeia of the Republic of Belarus, including general monographs on biological/biotechnological products, because their requirements apply to human cell lines included as components in products similar to BMCPs. The analysed approaches and methods of quality control of cell- and tissue-based products described in the USP and Ph. Eur. could form the basis for elaboration of general monographs for the Russian Pharmacopoeia, including identification, potency, viral safety, and mycoplasma tests that are based on the nucleic acid amplification technology and other tests for cell lines as components of BMCPs.
APA, Harvard, Vancouver, ISO, and other styles
4

Bouin, Anne-Sophie, and Michael Wierer. "Quality standards of the European Pharmacopoeia." Journal of Ethnopharmacology 158 (December 2014): 454–57. http://dx.doi.org/10.1016/j.jep.2014.07.020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shchukin, V. M., A. A. Erina, E. A. Lisman, and O. A. Vaganova. "Problems of Establishing Limits for Arsenic Content in Brown Algae and Brown Algae-Containing Medicinal Products." Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 9, no. 3 (September 10, 2019): 167–72. http://dx.doi.org/10.30895/1991-2919-2019-9-3-167-172.

Full text
Abstract:
Algae tend to accumulate elemental toxic substances in high concentrations. Algae are widely used in the food and pharmaceutical industries, and this dictates the need to establish limits for the content of toxic substances that they may contain. The aim of the study was to analyse the requirements of the Russian and foreign pharmacopoeias and other regulatory documents concerning the limits for the content of arsenic in brown algae. The paper presents the results of analysis of monographs from the State Pharmacopoeia of the Russian Federation, XIII and XIV editions, draft version of the Pharmacopoeia of the Eurasian Economic Union, United States Pharmacopoeia, Japanese Pharmacopoeia, European Pharmacopoeia, and Ayurvedic Pharmacopoeia of India containing limits for the content of arsenic in herbal medicinal products (HMPs). In addition, the authors analysed Russian, international and foreign food industry and dietary supplements regulations, as well as scientific publications on arsenic content in brown algae. They also considered the nomenclature of arsenic compounds to be determined and controlled in medicinal products, highlighted the main approaches to and identified global trends in establishing the limits for their content in HMPs. The paper summarises specific aspects of inorganic arsenic compounds accumulation by brown algae. It was demonstrated that the majority of foreign pharmacopoeias either have specific norms for arsenic content in brown algae, which differ from the norms for HMPs, or have general norms that take into account different toxicity levels of organic and inorganic arsenic compounds. There is a tendency to control the content of elemental toxic substances based on their maximum allowable daily intake. The paper substantiates the need for separate determination of toxic inorganic arsenic compounds and potentially toxic methyl arsonate and dimethyl arsinate in HMPs.
APA, Harvard, Vancouver, ISO, and other styles
6

Gray, Elaine, Trevor Barrowcliffe, and Barbara Mulloy. "Characterization of Unfractionated Heparin: Comparison of Materials from the last 50 Years." Thrombosis and Haemostasis 84, no. 12 (2000): 1052–56. http://dx.doi.org/10.1055/s-0037-1614170.

Full text
Abstract:
SummaryPhysicochemical and anticoagulant characteristics of 27 samples from recent batches of commercially produced unfractionated heparin have been determined as part of the process of establishment of the 5th International Standard Unfractionated Heparin. They have been compared with current heparin standards (European Pharmacopoeia, United States Pharmacopoeia, Chinese), with the 4th International Standard Unfractionated Heparin, and with the three predecessor International Standards. The results indicate that the 4th International Standard Unfractionated Heparin, established in 1982, has significantly lower molecular weight and specific activity than recently produced heparin; this is also true of all preceding International Standard Heparins and of the United States Pharmacopoeial standard. The composition of commercial unfractionated heparin may therefore have changed over time; reasons for this are discussed.
APA, Harvard, Vancouver, ISO, and other styles
7

Rzepa, Józef, Mieczysław Sajewicz, Tomasz Baj, Patrycja Gorczyca, Magdalena Włodarek, Kazimierz Głowniak, Monika Waksmundzka-Hajnos, and Teresa Kowalska. "A Comparison of Methodical Approaches to Fingerprinting of the Volatile Fraction from Winter Savory (Satureja montana)." Chromatography Research International 2012 (January 12, 2012): 1–8. http://dx.doi.org/10.1155/2012/596807.

Full text
Abstract:
It was the aim of this study to compare the efficiency of the different essential oil extraction methods upon the two winter savory (Satureja montana) samples of different origin. The compared techniques were the headspace gas chromatography with mass spectrometric detection (HS-GC/MS) run at the two different headspace temperatures (i.e., at 80 and 100°C) and the three different steam distillation techniques preceding the GC/MS analysis. HS-GC/MS is considered as the technique of the first choice, and the compared steam distillation techniques are recommended, respectively, by Polish Pharmacopoeia, European Pharmacopoeia, and the Polish Patent. Adequate conclusions were drawn as to the advantage of HS-GC/MS (not having the pharmacopoeial recommendation) over the different steam distillation techniques and the drawbacks of each individual analytical procedure were discussed.
APA, Harvard, Vancouver, ISO, and other styles
8

Melnyk, Halyna, Tatyana Yarnykh, and Marina Buryak. "Pharmacopeial aspects of preparation of infusions and decoctions in pharmacies." EUREKA: Health Sciences, no. 4 (July 30, 2021): 87–93. http://dx.doi.org/10.21303/2504-5679.2021.001971.

Full text
Abstract:
An analytical review of pharmacopoeial aspects of preparation of infusions and decoctions in pharmacies is presented. The aim of this work is to conduct a comparative analysis of pharmacopoeial requirements for the technology of infusions and decoctions in pharmacies. Materials and methods of the research. Comparative analysis of pharmacopoeial requirements was performed using methods of systematic and structural-logical analysis. Results and discussions. It was found that in many pharmacopoeias (European, British, Italian, French, Czech, Kazakh) there are no instructions on the pharmacy technology of these dosage forms. Only the pharmacopoeias of Japan, Austria, Belarus and Russia contain separate monographs on the extemporaneous preparation of infusions and decoctions. After analyzing these monographs, it was found that the definition of infusions and decoctions as a dosage form differs. It was found that the Japanese Pharmacopoeia regulates the preliminary preparation of medicinal plant raw materials (soaking for 5 minutes in water), in other pharmacopoeias there is no such requirement. When conducting a comparative analysis of the technology of preparation of infusions and decoctions, we observe that the ratio of medicinal plant raw materials (MPRM) and extractant and extraction modes differ. Conclusions. An analytical review of pharmacopoeial aspects of preparation of infusions and decoctions in pharmacies is presented. A comparative analysis of the requirements for technology and quality control of infusions and decoctions in accordance with pharmacopoeial articles revealed both different and similar information. The results of the research showed that despite the differences in the structures of articles and names, as well as approaches to the definition of this dosage form, some requirements are similar (particle size of MPRM). The differences that were found include the ratio of MPRM and extractant, extraction modes. Taking into account the data of the analysis and the existing national requirements, the authors proposed a draft general pharmacopoeial article “Infusions and decoctions made in pharmacies”.
APA, Harvard, Vancouver, ISO, and other styles
9

Khokhlova, K. O., O. A. Zdoryk, N. V. Sydora, and V. I. Shatrovska. "Chromatographic Profiles Analysis of Fruits of Crataegus L. Genus by High-Performance Thin-Layer Chromatography." European Pharmaceutical Journal 66, no. 2 (November 1, 2019): 45–51. http://dx.doi.org/10.2478/afpuc-2019-0020.

Full text
Abstract:
Abstract It was known that hawthorn - Crataegus L. is a polymorphic genus. Two hawthorn species and their hybrids are included in the European Pharmacopoeia, twelve – in Ukrainian pharmacopoeia. Determination of chromatographic profiles of hawthorn fruits species native to Ukraine and other countries that are non-pharmacopoeial, but have sufficient plant raw material base, is essential for quality control of drugs. Aim. To analyze and compare the chromatographic profiles of fruits of 23 Crataegus L. species on phenolic compounds, evaluated by means of high-performance thin-layer chromatography procedure (HPTLC), and determine the specific features of chromatographic fingerprints. Materials and Methods. A total of 39 samples of fruits of 23 hawthorn species that are native to Europe, Asia and North America, such as Crataegus monogyna, C. laevigata/C. oxyacantha, C. leiomonogyna, C. curvisepala, C. pseudokyrtostyla, C. fallacina, C. subrotunda, C. ambigua, C. pentagyna, C. sanguinea, C. chlorosarca, C. almaatensis, C.pseudoheterophylla subsp. turkestanica, C. pinnatifida, C. pentagyna subsp. pseudomelanocarpa, C. punctata, C. pringlei, C. festiva, C. douglasii, C. holmesiana, C. submollis, C. flabellata, C. canadensis were investigated. The analysis has been done following the TLC method from European Pharmacopeia modified into HPTLC, using automated HPTLC herbal system (CAMAG, Switzerland). The results have shown that chromatographic profiles of phenolic constituents of nine Crataegus L. species of Europe, both pharmacopoeial and non-pharmacopoeial, were quite similar, despite the significant morphological distinctions. The chromatographical profiles of three species of Asia were similar to the pharmacopoeial species; three other species looked different and had specific marker zones. In addition, eight Crataegus L. species of North America had specific markers helping for discriminative analysis from pharmacopoeial species. Conclusion. The findings could help to identify the possible adulterations and prevent the falsification of finished products. The results will be taken into consideration during revision of the Ukrainian national pharmacopoeial monograph for hawthorn fruits.
APA, Harvard, Vancouver, ISO, and other styles
10

Dymarczyk, Iwona. "Medicines from the first pharmacopoeia listed on the apothecary majolica vessels from the Mateusz B. Grabowski collection at the Museum of Pharmacy in Kraków." Opuscula Musealia 27 (2021): 169–83. http://dx.doi.org/10.4467/20843852.om.20.009.13748.

Full text
Abstract:
This article concerns medicinal preparations from the first European pharmacopoeia listed on the cartouches of apothecary majolica vessels (16th‒18th century) from the Grabowski collection at the Museum of Pharmacy in Kraków. The materials for comparison are three 16th-century works: Ricettario Fiorentino (1550), Pharmacopoea by J. Placotomus (1560) and Dispensatorium by V. Cordus (1563). The inscriptions on the apothecary jars for which they were meant comprise greatly important information carriers about medicine in the old days. Their deciphering can also be helpful when dating these objects.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "European Pharmacopoeia"

1

Borg, Ann-Louise. "Investigation of a Method for Determination of Anticomplementary Activity (ACA) in Octagam." Thesis, Linköping University, Department of Physics, Chemistry and Biology, 2009. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-21468.

Full text
Abstract:

This Master Thesis was conducted at Octapharma AB in Stockholm.

Anticomplementary activity (ACA) is a measure of the product’s abilities to activate the complement system. IgG aggregates are mainly responsible for this activation. Two different performances of a method for determination of ACA in Octagam® are available. The two performances are based on the reference method for test of ACA in immunoglobulins in the European Pharmacopoeia Commission Guideline 6.0 (chapter 2.6.17). The method is carried out either in test tubes or on microtiter plates. The test tube method can be performed either in a manual manner or modified, being more automated. The latter performance has been applied in this study. The plate method is more automated than both of the tube methods. The plate method and the manual tube method have earlier seemed to result in different outcomes, which was the basis for this thesis.

The plate method and the modified test tube method have been compared and robustness parameters have been studied in order to see which factors influence on the end result. The adequacy of using Human Biological Reference Preparation (human BRP) as a control for the ACA method in general has also been investigated. Samples of the product are outside the scope of this thesis and have not been investigated.

According to this study, the plate method and the modified tube method are not comparable with regard to complement titration results and to ACA of the BRP control. A higher precision is gained with the plate method. This in combination with the higher degree of automation makes the plate method advantageous in several aspects. When it comes to the robustness of the ACA method in general, the sheep red blood cells (SRBC) used are critical. Haemolysin dilution and complement activity seem to be critical as well.

Human BRP is, according to this study more adequate as a reference for the plate method than for the tube method. An In house control is believed to be more representative to the ACA method in general as it is of the same nature as the samples analysed, in contrast to the human BRP.

APA, Harvard, Vancouver, ISO, and other styles
2

Pouech, Charlene. "Développement de méthodologies analytiques pour l'étude de la migration depuis des contenants en matière plastique prévus pour des applications pharmaceutiques vers des solutions aqueuses et des fluides biologiques." Thesis, Lyon 1, 2014. http://www.theses.fr/2014LYO10118.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chang, Chih-Kai, and 張智凱. "Study two processes comply with the regulation of European pharmacopoeia in [18F] fluorothymidine and propose methods to shorten the time on quality control." Thesis, 2014. http://ndltd.ncl.edu.tw/handle/sekan6.

Full text
Abstract:
碩士
中山醫學大學
生物醫學科學學系碩士班
102
European Pharmacopoeia Eighth Edition was published in July 15 and replace d the 7th Edition on 1 January 2014. In this version adds a new radiotracer, [18F] fluorothymidine. [18F] fluorothymidine has been widely used in clinical diagnosis of disease, estimate the effect of tumor treatment and as a tool in the drug development process, quantify of it, all have a certain value in clinical and research, and has been published in domestic and foreign literature. According to the current Taiwan of the Pharmaceutical Affairs Law, the new drug application is required by Drug Company. , the drug manufacturers should submit the application to verify a new drug complied with relevant regulations, and obtain the drug license before it can legally supply to clinical practice. The drug should be produced on the qualified pharmaceutical company that conforms to the relevant specifications such as GMP, PIC / S, and be conducting regularly checks by the Ministry of Health and Welfare, the authority in Taiwan. Due to the time, cost, market and half-life of isotope and other factors, there are nine cyclotron centers set up in the medical centers of Taiwan. Because the commercial application for a new drug must conform "the checking notes of isotopes produced practice on positron emission tomography ", the main references are the United States Pharmacopoeia and the European Pharmacopoeia. The study used two kinds of processes produce [18F] fluorothymidine. One is IBA Synthera synthesis system, with the FLT components produced by the Huayi isotope company; the other is GE TracerLab MX synthesizer which is widely adopted by many cyclotron centers in the world with the FLT components produced by the advanced biochemical compounds company. The quality testing standards, according to the European Pharmacopoeia [18F] fluorothymidine test methods and acceptance criteria. The influence of products by the synthetic process of drug production methods, approaches, instruments, environmental conditions, and excipients, were disscussed in the thesis. That the quality control methods of [18F] fluorothymidine complied with the European Pharmacopoeia (8th edition) was focused in the text. We also propose experimental data shorten the time of quality control that may replace the method recommended by the European Pharmacopoeia.
APA, Harvard, Vancouver, ISO, and other styles
4

Pieroni, Andrea, and C. L. Quave. "Traditional pharmacopoeias and medicines among Albanians and Italians in southern Italy: a comparison." 2005. http://hdl.handle.net/10454/2990.

Full text
Abstract:
No
A cross-cultural comparison of traditional household remedies in primary health care and ritual healing practices in two economically and socio-demographically similar communities in Lucania (inland southern Italy) was considered: Ginestra/Zhurë, inhabited by ethnic Albanians, who migrated to the area during the 15th century, and Castelmezzano, inhabited by autochthonous South-Italians. In Ginestra/Zhurë, the number of traditional natural remedies (mainly derived from local medicinal plants) was only half of that in the local folk pharmacopoeia quoted in Castelmezzano. However, ritual magic-healing practices still play a central role among the Albanians in Ginestra/Zhurë, while they do not in Castelmezzano. Reasons for this shift, as well as components that have affected cultural adaptation phenomena and transitions among the Albanians are discussed.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "European Pharmacopoeia"

1

Europe, Council of. European pharmacopoeia. 2nd ed. Sainte-Ruffine, France: Maisonneuve S.A., 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Europe, Council of. European pharmacopoeia. 2nd ed. Sainte-Ruffine, France: Maisonneuve S.A., 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Europe, Council of. European pharmacopoeia. 2nd ed. Sainte-Ruffine, France: Maisonneuve S.A., 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Commission, European Pharmacopoeia, ed. European pharmacopoeia. 6th ed. Strasbourg: Council Of Europe, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Europe, Council of. European pharmacopoeia. 2nd ed. Sainte-Ruffine, France: Maisonneuve S.A., 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Europe, Council of. European pharmacopoeia. 2nd ed. Sainte-Ruffine, France: Maisonneuve S.A., 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Council of Europe. Directorate for the Quality of Medicines., ed. European pharmacopoeia. 5th ed. Strasbourg: Directorate for the Quality of Medicines, Council of Europe, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

European Pharmacopoeia. Interpharm Pr, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

European pharmacopoeia. 2nd ed. Sainte-Ruffine: Maisonneuve, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Distributors, Rittenhouse Book. European Pharmacopoeia. Rittenhouse Book Distributors, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "European Pharmacopoeia"

1

Nahler, Gerhard. "European Pharmacopoeia (Eur Ph)." In Dictionary of Pharmaceutical Medicine, 69. Vienna: Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-89836-9_515.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"Pharmacopoeial Standards: European Pharmacopoeia." In Encyclopedia of Pharmaceutical Science and Technology, Fourth Edition, 2691–703. CRC Press, 2013. http://dx.doi.org/10.1081/e-ept4-120050329.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Barret, Roland. "The European Pharmacopoeia." In Therapeutical Chemistry, 135–44. Elsevier, 2018. http://dx.doi.org/10.1016/b978-1-78548-288-5.50009-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"British Pharmacopoeia and the European Pharmacopoeia." In The British Pharmacopoeia, 1864 to 2014, 161–72. Routledge, 2016. http://dx.doi.org/10.4324/9781315614182-15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"The European Directorate for the Quality of Medicines and HealthCare, European Pharmacopoeia, and British Pharmacopoeia." In Pharmaceutical Medicine, edited by Adrian Kilcoyne, Phil Ambery, and Daniel O'Connor, 34–36. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199609147.003.0010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Compendial Requirements of Dissolution Testing—European Pharmacopoeia, Japanese Pharmacopoeia, United States Pharmacopeia." In Pharmaceutical Dissolution Testing, 87–98. CRC Press, 2005. http://dx.doi.org/10.1201/9780849359170-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Brown, William. "Compendial Requirements of Dissolution Testing—European Pharmacopoeia, Japanese Pharmacopoeia, United States Pharmacopeia." In Pharmaceutical Dissolution Testing, 69–80. Informa Healthcare, 2005. http://dx.doi.org/10.1201/9780849359170.ch3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"The Regulation of Biological and other Innovative Medicinal Products." In The Law and Regulation of Medicines and Medical Devices, edited by Anne Cook, John Johnston, and Louise Bisset, 60–86. Oxford University Press, 2021. http://dx.doi.org/10.1093/oso/9780192847546.003.0003.

Full text
Abstract:
This chapter discusses the phrase ‘biological medicinal product’, which is used to refer to products manufactured by biological or biotechnology means or to advanced therapy medicinal products. It examines biological medicinal products that are considered peptides or proteins and are made up of one or more linear sequences of amino acids. It also talks about the compliance of biological products with a minimum quality standard set by the British Pharmacopoeia or European Pharmacopoeia, which includes specific instructions for testing sterility, bacterial endotoxins, microbial limits, volume in container, uniformity of dosage units, and particulate matter. The chapter highlights biological products that are manufactured using recombinant cells and are extracted or made from unaltered tissues or blood that are purified in the same way as recombinant products. It explores the inherent heterogeneity of biological products as it comprises of a mixture of closely related molecules.
APA, Harvard, Vancouver, ISO, and other styles
9

Ligia, Duu. "Pharmacognostic Methods for Analysis of Herbal Drugs, According to European Pharmacopoeia." In Promising Pharmaceuticals. InTech, 2012. http://dx.doi.org/10.5772/36675.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"- In Vitro Antimicrobial Activities of Essential Oils Monographed in the European Pharmacopoeia 8th Edition." In Handbook of Essential Oils, 450–635. CRC Press, 2015. http://dx.doi.org/10.1201/b19393-18.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "European Pharmacopoeia"

1

Felicia, Suciu, Roșca Adrian Cosmin, Lupu Carmen, Popescu Antoanela, and Badea Victoria. "DETERMINATION OF POLYPHENOLIC COMPOUNDS OF LYSIMACHIA NUMMULARIA L." In GEOLINKS Conference Proceedings. Saima Consult Ltd, 2021. http://dx.doi.org/10.32008/geolinks2021/b1/v3/08.

Full text
Abstract:
"The history of medicinal plants is associated with the evolution of civilization. In all regions of the world, the history of nations shows that these plants have always occupied an important place in medicine, in cosmetic products, and culinary preparations. The paper aims to determine the total polyphenols in different parts of the species Lysimachia nummularia L. In our study, we focused on the extraction of polyphenolic compounds in different solvents. The solvents used in the extraction were: 40% ethanol, concentrated methanol, in water. The total polyphenol content was determined by spectrophotometric methods, a method from the European Pharmacopoeia 10.0, with minor modifications. The total polyphenol content of different extracts varied depending on the extraction process. Different parts of the plant and different solvents were used in the determinations carried out to establish the optimal extraction method for the organs of Lysimachia nummularia L."
APA, Harvard, Vancouver, ISO, and other styles
2

Valeriu Iancu, Valeriu, Laura Adriana Bucur, Verginica Schröder, and Manuela Rossemary Apetroaei. "PRELIMINARY STUDIES RELATED TO MICROSCOPY AND THE SEDEM EXPERT SYSTEM PROFILE ON FREEZED-DRIED EXTRACT OF LYTHRI HERBA." In GEOLINKS Conference Proceedings. Saima Consult Ltd, 2021. http://dx.doi.org/10.32008/geolinks2021/b1/v3/16.

Full text
Abstract:
"The floral tips of the plant species Lythrum salicaria L. represent a rich source of total polyphenols, among which with the largest share we mention tannins, and this is why this plant material has a standardized monograph in the European Pharmacopoeia 10.0th edition. According to the literature accessed so far, the plant material has antioxidant, anti-inflammatory, hemostatic, antibacterial and antifungal properties, along with modulatory action on carbohydrate metabolism. Powder microscopic examination is an important step in establishing the identity of the plant species used, highlighting elements specific to the aerial part such as spiral vessels of the stem, fragments of the spongy mesophyll with calcium oxalate clusters cells and anomocytic stomata. The application of the SeDeM method on dried plant extracts represents an innovative trend in pharmaceutical technology and contributes to the collection of data in a structured and standardized form. In this paper, the functions and applications of the SeDeM expert system are illustrated upon the freeze-dried extract of Lythri herba for the purpose of easier identification and standardization. Future applications may include obtaining chewable gums or tablets by direct compression."
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'European Pharmacopoeia' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography